Please login to the form below

Not currently logged in
Email:
Password:

TH-302

This page shows the latest TH-302 news and features for those working in and with pharma, biotech and healthcare.

Merck abandons evofosfamide as two trials fail

Merck abandons evofosfamide as two trials fail

The decision was taken after evofosfamide (TH-302) failed to show any improvement in overall survival in the trials, which involved patients with metastatic pancreatic cancer and soft tissue sarcoma who

Latest news

More from news
Approximately 2 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hanson Zandi

Hanson Zandi is a Creative and Digital Healthcare Agency. We combine 30 years’ experience with the enthusiasm of a start-up...

Latest intelligence

DNA
Why precision medicine demands precision engagement
The speed of innovation brings its own challenges, says cloud computing expert...
Unlocking the potential of science and technology in the UK
Greater collaboration is vital in post-Brexit UK, says Alderley Park leader...
NHS regional footprints
What to expect from 2019...

Infographics